A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

2019531 citationsJournal Articlebronze Open Access

Authors

George Dangas · National and Kapodistrian University of Athens

Jan G.P. Tijssen · Cardialysis (Netherlands)

Jochen Wöhrle · Universität Ulm

Lars Søndergaard · University of Copenhagen

Martine Gilard · Hôpital Maison Blanche

Helge Möllmann · St.-Johannes-Hospital Dortmund

Raj Makkar

Abstract

In patients without an established indication for oral anticoagulation after successful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily was associated with a higher risk of death or thromboembolic complications and a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.).

Topics & Keywords

Cardiac Valve Diseases and Treatments Infective Endocarditis Diagnosis and Management Atrial Fibrillation Management and Outcomes

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 2, pp. 120-129

DOI: 10.1056/nejmoa1911425

Field-Weighted Citation Impact: 53.10

Command Palette

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

Authors

Abstract

Topics & Keywords

Publication Details